The field of predictive medicine, one subsector in which the largely faded near-term promise of genomics maintains its color, is just where Myriad Genetics Inc. has wanted to be from the start - but not the only place. (BioWorld Financial Watch)

To survive in tough economic times, a biotech company often needs two things: cash and the ability to reach money and markets overseas.